IAM
COGT icon

Innovis Asset Management’s Cogent Biosciences COGT Stock Holding History

Innovis Asset Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$122K Sell
12,551
-10,303
-45% -$122K 0.05% 147
2023
Q2 		$271K Buy
22,854
+133
+0.6% +$1.53K 0.1% 127
2023
Q1 		$245K Buy
22,721
+165
+0.7% +$2.11K 0.1% 133
2022
Q4 		$261K Buy
+22,556
New +$280K 0.12% 119

Other funds holding COGT

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Innovis Asset Management's COGT Position: Q3 2023 in Review

Innovis Asset Management reduced its Cogent Biosciences (COGT) stake by 45% in Q3 2023, selling an estimated $122K and leaving 12,551 shares worth $122K. The position accounts for 0.05% of the portfolio, ranked #147.

Innovis Asset Management first reported a position in COGT in Q4 2022 and has held it in 4 quarters since. The position peaked at $271K in Q2 2023. 135 funds tracked by Wall St. Rank hold COGT as of Q3 2023.

  • Innovis Asset Management held 12,551 shares of Cogent Biosciences worth $122K as of Q3 2023.
  • Innovis Asset Management sold 10,303 Cogent Biosciences shares in Q3 2023, an estimated $122K.
  • Cogent Biosciences made up 0.05% of Innovis Asset Management's portfolio in Q3 2023, its #147 holding.
  • Innovis Asset Management first reported a position in Cogent Biosciences in Q4 2022 and has held it in 4 quarters since.
  • Innovis Asset Management's Cogent Biosciences position peaked at $271K in Q2 2023.
  • 135 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2023.

Based on Innovis Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.